Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca to Build ADC Manufacturing Facility in Singapore | Contract Pharma

What are you searching for?

Sign in
Breaking News

AstraZeneca to Build ADC Manufacturing Facility in Singapore

Will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

AstraZeneca has announced plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs).
 
The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.
 
Pascal Soriot, CEO, AstraZeneca, said: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.”
 
AstraZeneca has a broad portfolio of in-house ADCs including six wholly owned ADCs in the clinic and many more in preclinical development.
 
The company will work with Singapore’s government and other partners on green solutions for the ADC facility, which will be designed to emit zero carbon from its first day of operations.
 
AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness in 2029.
 
This news comes months after AstraZeneca invested $300 million in a facility in Rockville, MD.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics